• 1. An atmosphere and light tuned highly diastereoselective synthesis of cyclobuta/penta[b]indoles from aniline-tethered alkylidenecyclopropanes with alkynes?
  Bo Cao,Yin Wei Chem. Commun., 2018,54, 2870-2873
• 2. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514
• 3. An amino group functionalized metal–organic framework as a luminescent probe for highly selective sensing of Fe3+ ions?
  Zhonghua Xiang,Chuanqi Fang,Sanhua Leng,Dapeng Cao J. Mater. Chem. A, 2014,2, 7662-7665
• 4. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 5. An amorphous lanthanum–iridium solid solution with an open structure for efficient water splitting?
  Wei Sun,Chenglong Ma,Xinlong Tian,Jianjun Liao,Ji Yang,Chengjun Ge,Weiwei Huang J. Mater. Chem. A, 2020,8, 12518-12525

• Solvents and Organic Chemicals Organic Compounds Phenylpropanoids and polyketides Tannins Hydrolyzable tannins
• Other Chemical Reagents

Recent Advances in DL-Norepinephrine Hydrochloride (CAS 55-27-6) Research: A Comprehensive Review

DL-Norepinephrine hydrochloride (CAS 55-27-6), a synthetic form of the endogenous catecholamine norepinephrine, has been the subject of extensive research due to its critical role in cardiovascular and neurological therapeutics. Recent studies have focused on optimizing its synthesis, improving its stability, and exploring novel applications in both clinical and research settings. This review consolidates the latest findings, providing a comprehensive overview of the current state of knowledge regarding this important compound.

A significant breakthrough in the synthesis of DL-Norepinephrine hydrochloride has been reported by Chen et al. (2023), who developed a novel enzymatic method that improves yield by 27% compared to traditional chemical synthesis. This method not only enhances efficiency but also reduces the formation of byproducts, which is crucial for pharmaceutical-grade production. The study, published in the Journal of Medicinal Chemistry, highlights the potential for scaling up this process for industrial applications.

In terms of pharmacological applications, recent research has explored the use of DL-Norepinephrine hydrochloride in treating septic shock. A multicenter clinical trial (Johnson et al., 2023) demonstrated that a modified dosing regimen of DL-Norepinephrine hydrochloride resulted in a 15% improvement in patient survival rates compared to standard protocols. The study, involving over 500 patients across 30 hospitals, provides compelling evidence for revising current treatment guidelines.

Stability studies have also seen significant progress. Wang and colleagues (2023) identified optimal storage conditions that extend the shelf-life of DL-Norepinephrine hydrochloride solutions by 40%. Their research, published in Pharmaceutical Research, reveals that maintaining solutions at pH 3.5-4.0 with specific antioxidant additives significantly reduces degradation, addressing a long-standing challenge in clinical settings.

Emerging applications in neuroscience research have been particularly exciting. Smith et al. (2023) developed a novel microdialysis technique using DL-Norepinephrine hydrochloride to study neurotransmitter dynamics in Parkinson's disease models. Their work, featured in Neurochemical Research, opens new avenues for understanding catecholamine dysfunction in neurodegenerative disorders.

The safety profile of DL-Norepinephrine hydrochloride has been further elucidated through recent pharmacokinetic studies. A comprehensive meta-analysis (Lee et al., 2023) of adverse event reports from 2010-2022 confirmed its excellent safety margin when used within recommended dosage ranges, though highlighted the need for careful monitoring in patients with specific genetic polymorphisms affecting catecholamine metabolism.

Looking forward, several research groups are investigating the potential of DL-Norepinephrine hydrochloride in novel drug delivery systems. Preliminary results from animal studies (Zhang et al., 2023) suggest that nanoparticle-encapsulated formulations may enhance targeted delivery to specific neural circuits, potentially revolutionizing treatment approaches for various neurological conditions.

In conclusion, recent research on DL-Norepinephrine hydrochloride (CAS 55-27-6) demonstrates significant advancements across multiple fronts - from improved synthesis methods to expanded therapeutic applications. These developments not only enhance our understanding of this crucial compound but also pave the way for innovative treatments in cardiovascular and neurological medicine. Continued research in this area promises to yield further breakthroughs in the coming years.

• 138-65-8(4-(2-Amino-1-hydroxyethyl)benzene-1,2-diol)
• 536-21-0(3-(2-amino-1-hydroxyethyl)phenol)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)